Nephrocare Health Services IPO Day 1: Check Latest GMP, Subscription Status, Key Highlights, and More
NephroPlus (Nephrocare Health Services Ltd.), India’s and Asia’s largest dialysis service provider, has launched its Initial Public Offering (IPO) for public subscription today, December 10, 2025. Prior to the IPO opening, the company raised ₹260.3 crore from 14 anchor investors on December 9, 2025.
NephroPlus (Nephrocare Health Services) IPO: Issue Details
Issue Type: The NephroPlus (Nephrocare Health Services) IPO is a book-building issue of ₹871.05 crore, consisting entirely of a fresh issue of ₹353.40 crore and an offer for sale (OFS) of ₹517.64 crore.
Price Band: ₹438-₹460 per share.
Lot Size: 32 shares
Minimum Investment Amount: ₹14,016 per lot for retail investors.
IPO Closing Date: December 12, 2025
Allotment Date: The basis of allotment will be finalised by December 15, 2025
Listing Date: The tentative listing date on BSE and NSE is December 17, 2025.
Book running lead manager: ICICI Securities Ltd.
Registrar: Kfin Technologies Ltd.
NephroPlus IPO Day 1 Subscription Status
[10-December-2025 11:15:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.00 |
|
Non-Institutional Investors |
0.02 |
|
Retail Individual Investors (RIIs) |
0.05 |
|
Employees |
0.11 |
|
Total |
0.03 |
Utilisation of IPO Proceeds
The net proceeds from the fresh issue will be used towards the following objectives:
- General corporate purposes
- Fund capital expenditure for opening new dialysis clinics in India
- Repay/prepay outstanding borrowings availed by the company
NephroPlus IPO GMP
As per media reports, the Grey Market Premium (GMP) of the NephroPlus IPO is reported at nil. The shares are expected to list at par with the upper price band of ₹460 apiece.
NephroPlus Business Overview
NephroPlus (Nephrocare Health Services Ltd.) is India’s and Asia’s largest dialysis service provider, offering end-to-end renal care through a nationwide network of specialised centres. Their services cover every aspect of dialysis management, from clinical evaluation and ongoing treatment to patient support initiatives, across modalities such as in-centre haemodialysis, home-based dialysis solutions, and allied services, including pharmacy and renal wellness programmes.
The company is the only Indian dialysis services provider to have scaled internationally (Source: F&S Report), with a global network of 519 clinics, including 51 clinics in the Philippines, Uzbekistan, and Nepal (as of September 30, 2025).
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.